SCHEMBL2215331

SCHEMBL2215331

CC(C)(C)OC(=O)NCCC(C(=O)Nc1ccc(Nc2nc(-c3cccc4c3oc3ccccc34)cc3ccnn23)cc1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 2/20 0.33
ABL1 P00519 1/20 0.33
PDGFRB P09619 1/20 0.33
PDGFRA P16234 1/20 0.33
MAPK14 Q16539 1/20 0.33
ALDH1A1 P00352 2/20 0.31
LMNA P02545 2/20 0.31
HPGD P15428 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
HTT P42858 1/20 0.31
KMT2A Q03164 1/20 0.31
NCOA1 Q15788 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
NCOA3 Q9Y6Q9 1/20 0.31
MAPK1 P28482 3/20 0.31
CDC7 O00311 1/20 0.31
PLK4 O00444 1/20 0.31
CHEK1 O14757 1/20 0.31
DCLK1 O15075 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2215562 0.90 SUV39H2 (0.34) ALDH1A1LMNAHPGDKDM4EMEN1
SCHEMBL2214458 0.88 ROCK2 (0.42) SRCALDH1A1MAPK1CDC7PLK4
SCHEMBL2215145 0.83 BRD4 (0.36) ALDH1A1CDK1AURKB
SCHEMBL2213533 0.82 ROCK2 (0.35) SRCMEN1KMT2ANCOA1SMN1; SMN2
SCHEMBL2214698 0.79 BRD4 (0.38) KDM4EMAPK1CYP1A2
SCHEMBL2212315 0.79 MAPT (0.41) ALDH1A1LMNAHPGDKDM4EMEN1
SCHEMBL2212145 0.79 BRD4 (0.39) RPS6KB1
SCHEMBL2213364 0.78 NAMPT (0.36) KDM4EMEN1KMT2AMAPK1AKT1
SCHEMBL2215529 0.74 ALDH1A1 (0.38) ALDH1A1LMNAHPGDKDM4ESMN1; SMN2
SCHEMBL2213218 0.74 TRPV1 (0.42) ALDH1A1LMNAHPGDKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed
EP-1797096-A2 NOVEL PYRAZOLOPYRIMIDINES Altana Pharma AG (DE) 2007-06-20 EP disclosed
WO-2006027346-A2 NOVEL PYRAZOLOPYRIMIDINES ALTANA PHARMA AG (DE) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 SRC 3445/4885ABL1 1434/4885PDGFRB 2385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.